SHIFT

Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study – Lancet - 2010

Brief Summary:

In patients with symptomatic HFrEF (NYHA II-IV: LVEF ≤ 35%) with hospitalization for heart failure within the preceding year on contemporary medical therapy (i.e., ACE/ARB, beta blockers, and aldosterone antagonists) with resting heart rate ≥ 70bpm, the addition of ivabradine resulted in a 5% absolute reduction in heart failure mortality or hospitalization at 2 years. The benefit of ivabradine was driven both by a 5% absolute reduction in heart failure hospitalization as well as a 2% absolute reduction in heart failure mortality.

Reference: http://www.ncbi.nlm.nih.gov/pubmed/20801500